Posted on

elixir cbd peppermint oil oral spray dosage

The basics on oral sprays, including how to use them, how to determine how much to consume and the timing of onset of reported effects.

To figure out how much THC and CBD you are getting with each spray, take a look at the packaging to learn how much of the oil each spray delivers. For example, this oral spray comes in a 40 mL size, and the packaging states one spray equals 0.1 mL. The product contains 25 mg of THC per mL, and 30 mg of CBD per mL, so you’ll get 2.5 mg of THC and 3.0 mg of CBD per spray.

HIGHLIGHTS

As with other cannabis products, there is no recommended dosage. Every consumer will experience individual effects , depending on many factors, including sex, age, frequency of use and how much is consumed.

Shake the bottle well before using to ensure the extract is evenly mixed with the oil. Typical use is to push down on the pump and spray under your tongue or on the inside of your cheek.

Health Canada recommends starting with a low dose, such as one spray, and gradually increas ing it as the effects become apparent. If you’re new to cannabis, Health Canada recommends that you opt for a product with a mild THC level or equal or higher amounts of CBD , which has been reported anecdotally by cannabis consumers to counteract the psychoactive effects of the THC.

The “good drug effect” peaked at 3.7 h after each of the doses, except with 15 mg oral THC, for which Tmax was 4.5 h ( Figure 2a ). Visual analog scale (VAS) scores for “good drug effects” returned to baseline by 10.5 h. Post hoc comparisons revealed significantly greater “good drug effects” after 15 mg oral THC (avgdiff = 6.19 ± 1.64, P < 0.001) and high-dose Sativex (avgdiff = 3.79 ± 1.65, P = 0.022) as compared to placebo. Low-dose Sativex was associated with significantly higher (avgdiff = 3.33 ± 1.65, P = 0.044) “good drug effects” than 5 mg oral THC. Four participants had changes ≥40% after low-dose Sativex and three after 5 mg oral THC. “Good drug effects” were also greater (avgdiff = 6.82 ± 1.65, P < 0.001) after 15 mg vs. 5 mg oral THC. There were no significant differences in this regard between the results after low- and high-dose Sativex. The durations to mean maximum “good drug effects” were 2.9 ± 0.7 and 3.9 ± 0.7 h after 5 and 15 mg oral THC, respectively, and 3.5 ± 0.7 and 3.0 ± 0.6 h after low- and high-dose Sativex, respectively. Four of the participants who received low-dose cannabinoid, and three of those who received high-dose cannabinoid, did not report “good drug effects” >5% above baseline values.

Whole blood was collected through peripheral venous catheters into 7-ml tubes containing sodium heparin. The samples were stored on ice and then centrifuged within 2 h to separate plasma. Plasma was frozen in cryotubes at −20 °C until analysis.

Subjective effect scales

Although systolic blood pressure (SBP) tended to increase ( Figure 1a ), peaking at

In order to estimate physiological and subjective differences between drug conditions, changes relative to baseline values and relative to the placebo session were calculated after the administration of active drug treatments. Mixed models for repeated measures analysis of variance fit the data: changes in response measures relative to baseline and placebo were calculated as (drug condition + time + time × drug condition), where time denotes the data collection time point. Post hoc comparisons were carried out on the results of all active drug treatments with placebo and 5 to 15 mg oral THC, 5 mg oral THC with low-dose Sativex, 15 mg oral THC with high-dose Sativex, and low-dose Sativex with high-dose Sativex. SAS PROC MIXED was used for estimating mean differences (avgdiff ± standard errors) among placebo and the various active drug conditions, averaging across the post-baseline time points. In addition, time × treatment interactions were tested to ascertain whether the differences among the various treatment results varied significantly over time. Mean maximum responses were assessed by determining the maximum change from baseline and placebo for each participant and calculating the mean response and mean time at which maximum response occurred. To examine whether the administered drug had an effect on Likert scales, we computed changes in parameters relative to baseline and placebo in each drug condition and performed a Mantel–Haenszel χ-test stratified by participant to test for differences over time in mean change scores. With only nine subjects, and five drug conditions assigned in random order, it was impossible to test effectively for the existence of drug condition × sequence interaction effects.

After 15 mg oral THC, the concentration of THC in plasma was observed to have weak, but statistically significant, positive correlations with SBP and DBP (r ≤ 0.23), “good drug effect,” and “high” (r ≤ 0.35). Similarly, after high-dose Sativex, positive correlations (r ≤ 0.32) were also observed between plasma THC concentrations and “anxious,” “good drug effect,” “high,” “stimulated,” and M-scale scores.